全外显子组测序识别预后突变并验证分子国际预后评分系统在异基因造血干细胞移植后骨髓增生异常综合征中的作用
本研究采用全外显子组测序获取92例骨髓增生异常综合征患者移植前骨髓样本的基因组图谱,在45个驱动基因中鉴定出129个突变,55例(59.8%)携带至少1个驱动突变。U2AF1突变最常见(21例,23%)。WES还发现6个基因中49个可能致癌变异与移植后总生存或无复发生存相关,多因素分析显示DNAH5和USH2A突变是总生存的独立危险因素,DNAH5和LOXHD1突变是无复发生存的危险因素,分子国际预后评分系统在多因素分析后仍保持对无复发生存的独立预后意义。
要点
- 92例MDS患者移植前骨髓WES检出45个驱动基因129个突变,55例(59.8%)携带至少1个驱动突变。
- U2AF1突变最常见(21例,23%),其次为BCOR(9例,10%)、ASXL1(8例,9%)。
- DNAH5和USH2A突变是总生存独立危险因素,DNAH5和LOXHD1突变与更差无复发生存相关。
核心结论
- WES识别出与MDS移植后总生存或无复发生存相关的6个基因中49个可能致癌变异。
- DNAH5和USH2A突变是多因素分析中总生存的独立危险因素。
- DNAH5和LOXHD1突变是多因素分析中更差无复发生存的危险因素。
- 分子国际预后评分系统在多因素分析后仍保持对无复发生存的独立预后意义。
研究设计与样本
- 采用全外显子组测序获取92例骨髓增生异常综合征患者异基因造血干细胞移植前骨髓样本的基因组图谱。
主要发现
- 在45个驱动基因中鉴定出129个突变,55例(59.8%)携带至少1个驱动突变。
- U2AF1突变最常见(21例,23%),其次为BCOR(9例,10%)、ASXL1(8例,9%)、TET2(6例,7%)、NPM1(5例,5%)、RUNX1(5例,5%)、SETBP1(5例,5%)。
- WES鉴定出6个基因(PIEZO1、LOXHD1、MYH13、DNAH5、DPH1和USH2A)中49个可能致癌变异与移植后总生存或无复发生存相关。
- 多因素分析显示DNAH5和USH2A突变是总生存的独立危险因素。
- DNAH5和LOXHD1突变是更差无复发生存的危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we used the whole-exome sequencing (WES) approach to obtain genomic profiles from 92 marrow samples of myelodysplastic syndrome (MDS) patients before haematopoietic stem cell transplantation. We identified 129 mutations in 45 driver genes. Fifty-five patients (59.8%) carried at least 1 driver mutation. The splicing factor U2AF1 was the most frequently mutated in the cohort (21 cases, 23%), followed by BCOR (9 cases, 10%), ASXL1 (8 cases, 9%), TET2 (6 cases, 7%), NPM1 (5 cases, 5%), RUNX1 (5 cases, 5%), and SETBP1 (5 cases, 5%). WES also identified 49 possible oncogenic variants in six genes (PIEZO1, LOXHD1, MYH13, DNAH5, DPH1, and USH2A) that were associated with overall survival (OS) or relapse-free survival (RFS) in MDS after transplantation. Multivariate analysis showed mutations in DNAH5 and USH2A to be independent risk factors for OS. Mutations in DNAH5 and LOXHD1 were risk factors for worse RFS. The Molecular International Prognostic Scoring System retained its independent prognostic significance for RFS after multivariate analysis.
引用
- Wang H, Li X, Qi J, et al. Prognostic mutations identified by whole-exome sequencing and validation of the Molecular International Prognostic Scoring System in myelodysplastic syndromes after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024. PMID: 39138006. doi:10.1111/bjh.19707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。